Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Ayoxxa Biosystems GmbH. (1/21/13). "Press Release: Ayoxxa Biosystems Announces Signing of a Research Collaboration Agreement with the National University of Singapore as well as a Second Closing of the Series A Financing Round". Singapore & Cologne.

Organisations Organisation Ayoxxa Biosystems GmbH
  Group Ayoxxa (Group)
  Organisation 2 NUS Enterprise
  Group National University of Singapore (NUS)
Products Product In-situ Encoded Bead-based Arrays (IEBA)
  Product 2 venture capital
Index terms Index term Ayoxxa–SEVERAL: investment, 201209 financing round Series A €2.6m led by Wellington Partners
  Index term 2 Ayoxxa–National Univ Singapore: protein micorarray technology, 201301– collab r+d IEBA technology with Dept of Bioengineering at NUS
Persons Person Schmidt, Andreas (Ayoxxa 201201– Managing Director of Ayoxxa Biosystems GmbH)
  Person 2 Trau, Dieter (Ayoxxa 201209 CSO of Ayoxxa Bisoystems GmbH)
     


AYOXXA Biosystems, an international biotechnology company, announced today that it has added a second closing to its Series A financing round, with KfW Bankengruppe joining the ranks of investors. The recent 0.4 Mil Euro (0.6 million SGD) investment is an addition to the 2.6 million Euro (4.6 million SGD) Series A financing round closed in September 2012.

At the same time AYOXXA has entered a research collaboration agreement with the Department of Bioengineering, Faculty of Engineering, National University of Singapore (NUS) to further strengthen its discovery and development projects. This collaboration is expected to occur over a 2 year period and will be focused on developing the platform technology in relation to drug targets.

The resources will be used to drive the further development of AYOXXA's proprietary platform technology and the scale-up of production of its novel bead-based biochips as the company moves towards commercialization.

AYOXXA's technology is aimed at transforming the throughput and accuracy of protein analysis to deliver the analytical power now seen only for DNA arrays. The platform is based around proprietary "in-situ encoded bead arrays" (IEBA) exclusively licenced from NUS which allow the simultaneous measurement of multiple proteins from minute samples.

Unlike current bead-based microarrays, AYOXXA's IEBA need no physical label to allow multiplex analysis and thus hugely reduce the complexity of downstream analysis, while increasing the number of individual proteins that can be analysed at the same time. The arrays are designed to be readily adaptable to standard high throughput screening systems and offer the potential of tens of thousands of ELISA assays in a single well of a biochip.

Dr. Andreas Schmidt, CEO of AYOXXA, said: "We are excited to have another strong investor on board. The German KfW Bankengruppe is an ideal fit for AYOXXA as it has a long track record of successfully supporting technology companies and to ensure their presence in international markets."

Ms Irene Cheong, Director Industry Liaison Office, NUS said: "NUS is delighted to reinforce our partnership with AYOXXA, through this research collaboration. The fact that NUS technologies are being commercialised into applications to boost biomedical sciences research that could ultimately save lives, is indeed heartening. We look forward to seeing more of such innovations that are developed in an NUS laboratory having strong market relevance and making an impact."

Prof Dieter Trau, CSO of AYOXXA and Assistant Professor at NUS added: "We are very happy to continue our long term cooperation between NUS and AYOXXA with a formal research collaboration agreement. As a spin off company from NUS this has been already a very fruitful endeavour to develop an initial idea at the NUS Department of Bioengineering to the commercialization of our chip technology with AYOXXA.


About AYOXXA

AYOXXA, an international biotech company based in Cologne, Germany, and Singapore, has developed a proprietary technology platform for multiplexed protein analysis. Core to this cutting-edge technology are "in-situ encoded bead arrays" (IEBA) which allow simultaneous, precise and cost effective protein analysis in very small sample volumes.

These novel biochips allow users to combine high throughput screening and multiplexed assay formats at the same time and thus have the potential to revolutionize applications in biomedical research, pharmacological screening, and diagnostics.

AYOXXA was founded as a spin-off of the National University of Singapore (NUS) in 2010, and is supported by NUS Enterprise. The company received multiple grants in Singapore from the National Research Foundation (NRF), the SMART Innovation Centre (Singapore MIT Alliance for Research and Technology), and SPRING's Technology Enterprise Commercialisation Scheme (TECS). Current investors include Wellington Partners Venture Capital, NRW.Bank, HTGF - High-Tech-Gru¨nderfonds, KfW Bankengruppe and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems. AYOXXA established corporate headquarters in Cologne in Spring 2012, in addition to its operations in Singapore.


About NUS Enterprise

NUS Enterprise is a University-level cluster that provides an enterprise dimension to NUS teaching and research involving the University's students, staff and alumni. The functions of the Enterprise Cluster complement the academic cluster of the University to nurture talents with an entrepreneurial and global mindset. NUS Enterprise promotes the spirit of innovation and enterprise through Experiential Education, Industry Engagement & Partnerships and Entrepreneurship Support. The NUS Industry Liaison Office is a division of NUS Enterprise, and this manages and protects the University's intellectual property and promotes collaboration between NUS and industry. For more information, visit www.nus.edu.sg/enterprise


Contacts

Dr. Andreas Schmidt, CEO
AYOXXA Biosystems GmbH
BioCampus Cologne
Nattermannallee 1
50829 Köln, Germany
Phone:+49 (0) 221 222529-0
E-Mail: info@ayoxxa.com
www.ayoxxa.com


AYOXXA Living Health Technologies Pte. Ltd
National University of Singapore (NUS)
Block E3A, #07-02, 7 Engineering Drive 1
117576 Singapore
Phone: +65 65166482

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Ayoxxa (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top